Striatal molecular alterations in Huntington’s disease gene expansion carriers: A systematic review and meta-analysis of PET studies
Objective: To systematically examine the evidence of striatal molecular alterations in premanifest and manifest Huntington's disease gene expansion carriers (HDGECs) as measured by Positron emission…Single-subject FDG PET patterns and cognitive dysfunctions in Parkinson’s disease
Objective: To evaluate [18]FDG-PET single-subject perfusion patterns in Parkinson's disease (PD) patients and their relationship with cognitive dysfunction and progression during five years of follow-up.…Tau pathology in Huntington’s disease: A brief in vivo PET-imaging report
Objective: To assess feasibility of measuring pathological tau deposition in patients with Huntington's disease (HD) using [18F]-AV-1451 (f.k.a. T807) PET. Background: HD is a progressive…Participation in cognitively-stimulating activities and computer use are associated with better cognitive performance in Parkinson’s disease independent from nigrostriatal dopaminergic and cortical cholinergic degenerations
Objective: To investigate the relationship between times spent with cognitively stimulating activities and cognitive functions in Parkinson's disease (PD) while accounting for the degree of…Treatment of lipopolysaccharide-induced parkinsonism
Objective: This single case report of levodopa-responsive parkinsonism, caused by an accidental systemic contamination with 10 microgram lipopolysaccharides (LPS) from Salmonella minnesota, describes the treatment…THK-5351 tau-tracer uptake in patients with clinically diagnosed progressive supranuclear palsy
Objective: The objective of our study is to investigate characteristics of THK-5351 binding in patients with clinically diagnosed progressive supranuclear palsy (PSP) and correlate tau-tracer…Staging of cognitive impairment: Validation of a novel cognitive score with [18F]FDG-PET
Objective: To provide insight into the nature of cognitive deterioration and Parkinson's disease dementia (PDD) and to validate a novel cognitive score (also submitted for…Quantification of striatal dopamine transporters with [18F]PR04.MZ in patients with progressive supranuclear palsy and Parkinson’s disease
Objective: To evaluate the differences in striatal subregional dopamine transporter loss in Parkinson's disease (PD) and supranuclear palsy (PSP) and the diagnostic value of [18F]PR04.MZ…[18F]AV-1451 PET imaging of tau in progressive supranuclear palsy and Alzheimer’s disease
Objective: To evaluate: (1) brain tau pathology in vivo in patients with Progressive Supranuclear Palsy (PSP) and Alzheimer's disease (AD); (2) whether brain tau pathology…The relationship between the cognitive phenotype and 5-HT2A receptor in PD with visual hallucinations
Objective: The aim of this study was to investigate the relationship between cognitive phenotype and 5-HT2A receptor availability in PD patients with visual hallucinations (VH).…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.